Stockholm

• PREDIX HER2 - preoperative treatment of HER2 positive breast cancer Ended recruitment
  2023-508411-23-00 4 2014-11-12 Primary breast cancer
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke Halted
  2023-506178-11-00 5 2025-11-11 Acute ischemic stroke
• CAPSI - Cancer related major depression treated with a single dose of psilocybin - a multicenter randomized placebo controlled double blind … Halted
  2023-505532-35-00 4 2024-05-15 Major Depressive Disorder
• Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization Ended
  2024-512651-20-00 4 2024-11-20 Fetal and Neonatal Alloimmune Thrombocytopenia due to Human Platelet A
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A safety and efficacy study of ARGX-119 in adult patients with Amyotrophic Lateral Sclerosis (ALS) (reALiSe) Ended
  2024-511318-19-00 4 2024-10-23 Amyotrophic Lateral Sclerosis (ALS)
• Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dos … Ended
  2023-506000-50-00 4 2024-09-26 Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-H
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit … Ended
  2023-506335-15-00 5 2024-07-18 Major Depressive Disorder
• AMX0035 and Progressive Supranuclear Palsy Ended
  2023-505893-14-00 5 2024-06-04 Progressive Supranuclear Palsy
• A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap … Ended
  2022-502653-34-01 11 2024-05-30 Atopic dermatitis and moderate-to severe atopic hand eczema
• Long Term Outcomes Ended
  2023-505098-34-00 6 2024-04-22 Opioid Use Disorder
• A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Latera … Ended
  2023-506509-21-00 3 2024-03-08 Amyotrophic Lateral Sclerosis
• A24110He in a placebo-controlled trial evaluating safety in subjects with elevated plasma triglycerides Ended
  2023-509091-42-00 4 2024-02-27 Moderate to severe hypertriglyceridemia
• A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended
  2022-501310-57-00 4 2024-02-05 Endometriosis related pain
• A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended
  2022-502529-17-00 5 2024-01-18 Obesity
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• Study to investigate the efficacy of chaste tree (Vitex agnus-castus BNO 1095 (20 mg)) in women with cramping pain in the lower abdomen occu … Ended
  2023-503688-41-00 5 2023-11-28 Primary Dysmenorrhea
• A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o … Ended
  2023-509833-38-00 5 2023-09-20 Birch Pollen-induced Allergic Rhinoconjunctivitis
• A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder Ended
  2022-502077-42-00 10 2023-09-14 generalised anxiety disorder
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended
  2022-502234-70-00 5 2023-07-14 Chronic Obstructive Pulmonary Disease (COPD)
• A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended
  2023-508163-74-00 5 2023-06-12 Major Depressive Disorder

Showing 193–216 of 243 trials